In November 2021, the FDA approved the combination of subcutaneous Darzalex Faspro (daratumumab and hyaluronidase) plus Kyprolis (carfilzomib) and dexamethasone for adults with relapsed or refractory multiple myeloma who have received previous therapy.
A thorough overview of multiple myeloma, including an understanding of treatment options, the importance of patient and doctor communication, and an oncology navigator’s experience treating this form of blood cancer.
Nurse practitioner Beth Faiman, PhD, MSN, an expert in multiple myeloma, briefly discusses the unique features of this uncurable but very treatable cancer, highlighting that getting what you want out of treatment requires arming yourself with knowledge about the disease, evaluating your treatment goals, familiarizing yourself with your treatment team, and becoming an active participant in your treatment.
Last modified: October 3, 2017
Subscribe to CONQUER™: the patient voice™ magazine
Receive timely cancer news & updates, patient stories, and more.